Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Background: Glioblastoma is a common brain cancer in adults. Treatment includes surgery, radiation, and chemotherapy. But this cancer can return after treatment and is often fatal. Researchers want to know if a study drug (LMP744) can kill glioblastoma tumor cells. Objective: To test LMP744 in people with glioblastoma. Eligibility: People aged 18 years or older with glioblastoma that returned after treatment. Design: Participants will be screened. They will have a surgery to remove a small sample of tumor tissue (biopsy) from the brain. This will be done under protocol 03-N-0164. They will stay in the clinic for 1 night. They will also have imaging scans and tests of their heart function. Participants will have a central line installed: A flexible tube will be inserted into a vein in the chest. It will be attached to a port under the skin. This port will be used to draw blood and give medicines without having to insert new needles into a vein. LMP744 will be given through the central line for 5 days in a row. Participants will remain in the clinic for this time. Participants will then have a second surgery to remove as much of their tumor as possible. They will remain in the clinic until they recover from the surgery. Then they will recover at home after surgery. Participants will return to the clinic to receive the study drug for 5 days in a row through the central line, once a month for up to 12 months. Blood tests, heart function tests, and periodic imaging scans will be repeated during these visits. Participants will continue to have telehealth visits every 3 months after they stop taking the drug.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Osoby powyżej 18 lat.
- •Zdiagnozowany nawrotowy glejak, który nie ma określonych mutacji genetycznych (IDH-wildtype).
- •Ogólny stan zdrowia pozwalający na aktywność (KPS > 60).
- •Zgoda na stosowanie skutecznej metody antykoncepcji (zarówno kobiety, jak i mężczyźni) przez czas trwania badania i 6 miesięcy po nim.
- •Zgoda na zabieg chirurgiczny mózgu w celu pobrania wycinka guza i/lub jego usunięcia.
- •Zgoda na wyznaczenie osoby do podejmowania decyzji w sprawach zdrowotnych w przypadku utraty świadomości.
- •Zgoda na udział w badaniu lub zgoda przedstawiciela prawnego, jeśli osoba nie może jej udzielić samodzielnie.
✗ Disqualifies
- •Kobiety w ciąży lub karmiące piersią.
- •Poważne choroby współistniejące, które mogą uniemożliwić tolerowanie leku (np. niekontrolowana choroba nerek lub niewydolność serca).
- •Sytuacje społeczne, które mogą utrudniać przestrzeganie zasad badania.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 99 Years
- Last updated (source)
- July 20, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
National Institutes of Health Clinical Center
Bethesda, United States
Trial contact
Sadhana Jackson, M.D.
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/3/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.